Compare iShares MSCI Australia ETF (EWA) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Johnson & Johnson — how do they compare? iShares MSCI Australia ETF trades at $28.5 (market cap $1.17B), while Johnson & Johnson trades at $261.04 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 528.3× iShares MSCI Australia ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while iShares MSCI Australia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 63 Days and Johnson & Johnson for 129 Days on average.
| EWA | JNJ | |
|---|---|---|
Market Cap | $1.17B | $618.09B |
Volume | 2,121,231 | 6,050,983 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $278.43 |
52-Week Low | $24.95 | $186.00 |
Typical Hold Time | 63 Days | 129 Days |
Enterprise Value | — | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Australia ETF (EWA) trades at $28.465, up 0.83% today, but technical indicators signal a bearish trend with all moving averages in sell territory. The ETF, which tracks Australian equities, faces headwinds from domestic market volatility and inflation concerns, as Australian shares recently hit a three-month low. Key support and resistance cluster tightly around $28, indicating a critical price zone. Financial ratios are unavailable in the provided data, limiting fundamental assessment.
Outlook remains cautious due to technical weakness and macroeconomic pressures, though some analysts see upside potential from commodity exposure. Risks include persistent inflation, tight monetary policy, and global economic shifts. Investors should weigh the bearish technicals against Australia's resource-driven economic prospects.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
